CoChat

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

Open access

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Background: HER2 overexpression/amplification in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) may be associated with resistance to standard-of-care anti-EGFR therapies. Given the lack of comprehensive investigations into this association, we assessed the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes. Methods: A systematic review of MEDLINE, Embase, and Cochrane Library (2001-2021) identified studies evaluating progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) in HER2-positive vs. HER2-negative patients with RAS WT mCRC who received anti-EGFR treatments and whose HER2 status was known. Meta-analyses of proportions (ORR) and hazard ratios (PFS, OS) were performed using random-effect models with pre-specified sensitivity analyses. Results: Five high-quality retrospective cohort studies were included in the meta-analyses representing 594 patients with mCRC. All patients received anti-EGFR treatment, either as monotherapy or in combination with chemotherapy. Meta-analysis of PFS demonstrated a 2.84-fold higher risk of death or progression (95% CI, 1.44-5.60) in patients with HER2-positive (vs. HER2-negative) RAS WT mCRC treated with anti-EGFR regimens. The odds of response to anti-EGFR treatment were 2-fold higher in HER2-negative vs. HER2-positive (odds ratio, 1.96 [95% CI, 1.10-3.48]). Differences in OS were not statistically significant. Sensitivity analyses confirmed the robustness of the base-case estimates. Conclusions: While this study could not account for all confounding factors, in patients with RAS WT mCRC who received anti-EGFR therapy, HER2 overexpression/amplification was associated with worse PFS and ORR and may therefore predict poorer outcomes. HER2 testing is important to inform treatment decisions and could optimize outcomes for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/oncolo/oyad200

Cites

34 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. PRISMA flow of citations screened through the SLR process. *Fourteen publications reporting on 12 studies that were subject to meta-analysis feasibility assessment. **Nine publications reporting on 5 studies included in meta-analysis. Abbreviations: Cochrane Library, The Cochrane Central Register of Controlled Trials; CRC, colorectal cancer; Embase, Excerpta Medica Database; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; MEDLINE, Medical Literature Analysis and Retrieval System Online; NGS, next-generation sequencing.
Figure 1. PRISMA flow of citations screened through the SLR process. *Fourteen publications reporting on 12 studies that were subject to meta-analysis feasibility assessment. **Nine publications reporting on 5 studies included in meta-analysis. Abbreviations: Cochrane Library, The Cochrane Central Register of Controlled Trials; CRC, colorectal cancer; Embase, Excerpta Medica Database; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; MEDLINE, Medical Literature Analysis and Retrieval System Online; NGS, next-generation sequencing.CC BY · PubMed Central
Figure 2. Meta-analysis of PFS with anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,15,16,25-29 HR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in the risk of death or progression on anti-EGFR treatment (represented by the gray vertical line); HR > 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-positive group compared with HER2-negative group; HR < 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of PFS for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mCRC, metastatic colorectal cancer; PFS, progression-free survival; WT, wild-type.
Figure 2. Meta-analysis of PFS with anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,15,16,25-29 HR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in the risk of death or progression on anti-EGFR treatment (represented by the gray vertical line); HR > 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-positive group compared with HER2-negative group; HR < 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of PFS for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mCRC, metastatic colorectal cancer; PFS, progression-free survival; WT, wild-type.CC BY · PubMed Central
Figure 3. Sensitivity analysis excluding outlier study (Raghav 2016/2019) from meta-analysis of PFS with anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,15,25-27,29 HR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in the risk of death or progression on anti-EGFR treatment (represented by the gray vertical line); HR > 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-positive group compared with HER2-negative group; HR < 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of PFS for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mCRC, metastatic colorectal cancer; PFS, progression-free survival; WT, wild-type.
Figure 3. Sensitivity analysis excluding outlier study (Raghav 2016/2019) from meta-analysis of PFS with anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,15,25-27,29 HR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in the risk of death or progression on anti-EGFR treatment (represented by the gray vertical line); HR > 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-positive group compared with HER2-negative group; HR < 1 signifies higher risk of death or progression on anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of PFS for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mCRC, metastatic colorectal cancer; PFS, progression-free survival; WT, wild-type.CC BY · PubMed Central
Figure 4. Meta-analysis of ORR to anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,26,27,29 OR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in response to anti-EGFR treatment (represented by the gray vertical line); OR < 1 signifies higherodds of response to anti-EGFR treatment in HER2-positive group compared with HER2-negative group; OR > 1 signifies higher odds of response to anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of ORR for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; mCRC, metastatic colorectal cancer; OR, odds ratio; ORR, objective response rate; WT, wild-type.
Figure 4. Meta-analysis of ORR to anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,26,27,29 OR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in response to anti-EGFR treatment (represented by the gray vertical line); OR < 1 signifies higherodds of response to anti-EGFR treatment in HER2-positive group compared with HER2-negative group; OR > 1 signifies higher odds of response to anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of ORR for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; mCRC, metastatic colorectal cancer; OR, odds ratio; ORR, objective response rate; WT, wild-type.CC BY · PubMed Central
Figure 5. Meta-analysis of OS with anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,15,25-27 HR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in response to anti-EGFR treatment (represented by the gray vertical line); HR < 1 signifies higher odds of response to anti-EGFR treatment in HER2-positive group compared with HER2-negative group; HR > 1 signifies higher odds of response to anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of OS for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mCRC, metastatic colorectal cancer; OS, overall survival; WT, wild-type.
Figure 5. Meta-analysis of OS with anti-EGFR treatment in patients with RAS WT mCRC who were HER2-positive compared with patients with mCRC who were HER2-negative.11,12,15,25-27 HR = 1 signifies no statistically significant differences between HER2-positive and HER2-negative groups in response to anti-EGFR treatment (represented by the gray vertical line); HR < 1 signifies higher odds of response to anti-EGFR treatment in HER2-positive group compared with HER2-negative group; HR > 1 signifies higher odds of response to anti-EGFR treatment in HER2-negative group compared with HER2-positive group; the exact effect size of OS for the meta-analysis is represented by the vertical red line. Abbreviations: CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mCRC, metastatic colorectal cancer; OS, overall survival; WT, wild-type.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 1

  1. Kang, 2021, Systematic literature review of HER2 amplification/overexpression in colorectal cancer, J Manag Care Spec Pharm, 27, C6

Cited by

See all 38

Metadata

Authors
Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H.
Affiliations
  • Division of Hematology/Oncology, Mayo Clinic , Phoenix, AZ , USA
  • Maple Health Group, LLC , New York, NY , USA
  • Seagen (United States) (US)
  • Duke Medical Center (US)
Corresponding author
Strickler, John H
Venue
The Oncologist
Published
2023-07-18
Volume
28
Issue
10
Pages
885-893
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W4384625387
Cited by
36
References
34
Citations by year
2026: 10 · 2025: 12 · 2024: 12 · 2023: 2
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Seagen Inc
  • Merck Sharp & Dohme Corp
  • Merck & Co., Inc
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
HER2 overexpression, HER2 amplification, metastatic colorectal cancer, RAS wild-type, anti-EGFR therapy, progression-free survival, overall response rate, overall survival, predictive biomarkers, HER2 testing, treatment resistance
MeSH terms
Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Rectal Neoplasms, Retrospective Studies, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. https://app.cochat.ai/papers/10.1093/oncolo/oyad200
The paper
Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023). Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. The Oncologist. https://doi.org/10.1093/oncolo/oyad200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.